Details of the Drug

General Information of Drug (ID: DMLRIIP)

• Drug Name: CMD-003

Indication

Disease Entry	ICD 11	Status	REF
Lymphoma	2A80-2A86	Phase 2	[1]
Non-hodgkin lymphoma	2B33.5	Phase 2	[2]

• Cross-matching ID: TTD ID: D03EZR
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

References

• [1] ClinicalTrials.gov (NCT01948180) Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)